Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!

Increasing obesity levels, high genetic vulnerability and increasing urbanization rates are expected to be the catalysts in driving the prevalence of diabetes in India. Research firm IMARC Group expects India’s diabetes population to increase at a CAGR of 3% during 2013-2020, according to its latest report titled “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti-diabetics, Insulin and Diagnostics”. The report which has done a comprehensive analysis on the market for diabetic drugs and diagnostics, expects 78 Million Indians to suffer from diabetes by 2020, creating a huge demand for oral antidiabetic drugs, insulin and diagnostics.

According to Sidhartha Kapoor, an analyst at IMARC Group,“the Indian population that had faced under nutrition for a long time is now exposed to high fat diets and sedentary lifestyles. As a result of increasing disposable incomes and flourishing fast food chains, India had an estimated 165 Million overweight and 30 Million obese population in 2013. These levels are expected to increase significantly in the coming years”. Apart from the increasing obesity levels, Kapoor also pointed out that a high genetic vulnerability is also driving the prevalence of diabetes in the country. According to Kapoor- “As a result of a higher percentage of body fat to muscle, Indians are more vulnerable to type-2 diabetes compared to other population groups. This fat increases the sugar levels as it gets deposited around the abdomen and interferes with insulin. As a result, Indians get diabetes at a much younger age compared to other population groups”.

IMARC’s new report “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti-diabetics, Insulin and Diagnostics” provides an analytical and statistical insight into the Indian diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in India. The report has segmented the Indian diabetes market into three segments - Oral Anti-diabetics, Insulin and Diabetes Diagnostics. For each of the aforementioned categories, the report provides historical and future market sales, performance of key classes and the performance of top players.

The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Indian diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Indian diabetes market in some form or the other.

What we have achieved in this report:

Comprehensive situation analysis of the Indian Diabetes Epidemiology and its dynamics:
Focus of the Analysis:
• Historical, current and future prevalence of diabetes in India
• Historical, current and future prevalence of type-1 and type-2 diabetes in India
• Historical, current and future prevalence of diabetes in the urban and rural regions in India
• Historical, current and future prevalence of diabetes among males and females in India
• Historical, current and future prevalence of diabetes among various age groups in India
• Historical, current and future diagnosis rates for diabetes in India
• Historical, current and future drug treatment rates for diabetes in India

Comprehensive situation analysis of the Indian Oral Anti-diabetics market and its dynamics:
Focus of the Analysis:
• Performance of the Oral Anti-diabetics market in India
• Performance of key classes
• Performance of key players
• Market outlook

Comprehensive situation analysis of the Indian Insulin market and its dynamics:
Focus of the Analysis:
• Performance of the Insulin market in India
• Performance of key classes
• Performance of key players
• Market outlook

Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.